Amgen's (AMGN) Cholesterol Drug Is Very Important, Says JIm Cramer

We recently published 12 Fresh Stocks Jim Cramer Discussed Along With His Latest Thoughts On Quantum Computing. Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer recently discussed.

Amgen Inc. (NASDAQ:AMGN) is a drug company that makes and sells medicines for a wide variety of ailments, such as arthritis and ulcers. Just like he believes that Pfizer needs to showcase new products to excite investors, Cramer also holds the same opinion for Amgen Inc. (NASDAQ:AMGN). While his comments about the firm were brief in this episode, they were quite important as they tied into what Cramer said about the company in August. Back then, he outlined that he took a medicine called Repatha for cholesterol. The CNBC TV host wished that Amgen Inc. (NASDAQ:AMGN) offered the drug in pill form. In this episode, he mentioned Repatha again:

“I’ve got Amgen, they’ve got a, they have something that is going to be used for weight but the really big thing is Repatha, which is their drug for cholesterol. It’s very important.”

Here’s what Cramer said about Amgen Inc. (NASDAQ:AMGN) and Repatha in August:

“I take medicine, called Repatha, by the way, which is really good, it’s an Amgen medicine. It lowers cholesterol, and it’s said to be maybe removing plaque from your . . . You want that. But David. It hurts like you wouldn’t believe it, like a banshee. Like a banshee. I mean every Sunday, I’m like aaaaah, now maybe it’s because I’m sensitive. Kind of like your dial up, pssh khwuuum. . .and I wish it were [available in oral form] because boy it’s an amazing medication. I think I wish for Amgen, get than thing in a pill form, everybody in the world would be taking it. Stock’s at 285, sells at 13 times earnings, that’s crazy.”

While we acknowledge the potential of AMGN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.